Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AstraZeneca
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A Phase I, Randomized, Open-Label, Multi-National Study to Evaluate the Pharmacokinetics of Repeated Once-Daily Intravenous Doses of Esomeprazole in Paediatric Patients 0 to 17 Years Old, Inclusive
The primary objective is to evaluate the pharmacokinetics of repeated doses of esomeprazole given as an once daily (qd) injection over 3 minutes in paediatric patients 0 to 17 years old, inclusive, by...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A clinical trial to investigate the effects of tralokinumab, a drug used in clinical research, in adults with uncontrolled, severe asthma, a disease that causes variable and recurring inflammation of the airways leading to difficulty in breathing
To evaluate two SC treatment regimens of 300 mg tralokinumab compared with placebo by assessing the effect on asthma exacerbation rate over 52 weeks in adults with uncontrolled, severe asthma requirin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Multi-Centre Phase IIa Study to Assess the Effects on Biomarkers in Induced Sputum, Blood and Urine of AZD1236 Administered as Oral Tablet in Moderate to Severe COPD Patients During a 6 Week Treatment Period
The primary objective is to assess the effects of AZD1236 compared with placebo on selected biomarkers in induced sputum, urine and blood in patients with moderate to severe chronic obstructive pulmon...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca K.K
MAJ Il y a 5 ans
A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children age 2 years through 6 years
To assess the safety and tolerability of MEDI3250.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
MedImmune LLC(a wholly owned subsidiary of AstraZeneca PLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA )
MAJ Il y a 5 ans
A clinical trial to investigate the effects of MEDI9929, a drug used in clinical research, in adults with uncontrolled, severe asthma, a disease that causes variable and recurring inflammation of the airways leading to difficulty in breathing
To evaluate the effect of MEDI9929 on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A 6-week, phase III, double-blind, randomized, multi-centre, parallel-group study evaluating the efficacy and safety of 2 actuations Symbicort® (budesonide/formoterol) pMDI 40/2.25 μg twice daily compared with 1 inhalation Symbicort Turbuhaler® 80/4.5 μg twice daily and 1 inhalation Pulmicort® (budesonide) Turbuhaler® 100 μg twice daily in adult and adolescent asthmatics
To show that Symbicort pMDI 40/2.25 μg two actuations b.i.d.(delivered dose) is more efficacious than Pulmicort Turbuhaler 100 μg one inhalation b.i.d. (metered dose) over a 6-week treatment period in...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca A/S
MAJ Il y a 5 ans
Acutely Manic Patients Insufficiently Responding After 2 Weeks Continued Quetiapine Monotherapy: Continued Quetiapine Versus Sodium Valproate Add-on
The primary objective is to investigate whether the addition of sodium valproate will be superior to treatment with quetiapine given as mono-therapy for an additional 14 days in non-responding patient...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca S.A.S
MAJ Il y a 5 ans
Evaluation de l’efficacité de 3 stratégies de prise en charge au long cours des symptômes de reflux gastro-oesophagien en médecine générale : étude multicentrique, randomisée, en ouvert, réalisée en groupes parallèles
Comparer, en médecine générale, chez des patients présentant des symptômes attribués à un reflux gastro-oesophagien (RGO), l’efficacité de trois stratégies de traitement au long cours, selon la sévéri...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
Comparing the efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg dose levels, to allow for a switch from Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
The primary objective is to demonstrate therapeutic equivalence between Bricanyl Turbuhaler M3 and Bricanyl Turbuhaler M2 using bronchoprotective effect as outcome measure. Outcome measurements: PC...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden
MAJ Il y a 5 ans
A clinical study to assess the benefits of aclidinium bromide/formoterol fumarate (active treatment) compared with placebo (comparator) in lung volumes, exercise capacity and physical activity after 8-weeks of treatment in symptomatic patients with chronic obstructive pulmonary disease (COPD). The study is "randomised" (equal chance of receiving active treatment or comparator) and "double blind" (neither patients nor the study doctor will know the treatment). Ensayo clínico para evaluar los beneficios de bromuro de aclidinio/formoterol fumarato (tratamiento activo) comparado con placebo (comparador) en volúmenes pulmonares, capacidad de ejercicio y actividad física tras 8 semanas de tratamiento en pacientes sintomáticos con enfermedad pulmonar obstructiva crónica (EPOC). El estudio es aleatorizado ( igual probabilidad de recibir tratamiento activo y comparador) y doble ciego ( ni los pacientes ni el doctor del estudio sabrán el tratamiento recibido)
To evaluate the effect of aclidinium bromide/formoterol 400/12 micrograms fixed dose combination (FDC) BID on lung hyperinflation compared with placebo in patients with moderate to severe chronic obst...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
19
20
21
22
23
24
25
26
27
28
Suivant